Solesence, Inc. Common Stock
Solesence, Inc., a science-driven company, develops, manufactures, and sells integrated family of technologies in the United States. The company engages in engineered materials, formulation development, and commercial manufacturing. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients under the Solésence brand; skin heal… Read more
Solesence, Inc. Common Stock (SLSN) - Total Liabilities
Latest total liabilities as of September 2025: $36.76 Million USD
Based on the latest financial reports, Solesence, Inc. Common Stock (SLSN) has total liabilities worth $36.76 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Solesence, Inc. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Solesence, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Solesence, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Solesence, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nice D&B Co. Ltd
KQ:130580
|
Korea | ₩22.48 Billion |
|
V-Tac Technology Co Ltd
TWO:6229
|
Taiwan | NT$957.34 Million |
|
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
|
Turkey | TL2.59 Billion |
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
Turkey | TL11.85 Million |
|
JMT Co.Ltd
KQ:094970
|
Korea | ₩73.37 Billion |
|
UNITRAD
KLSE:0247
|
Malaysia | RM749.95 Million |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
Malaysia | RM238.77 Million |
|
MEI Pharma Inc
NASDAQ:MEIP
|
USA | $1.35 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Solesence, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Solesence, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Solesence, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of Solesence, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $35.06 Million | +13.16% |
| 2023-12-31 | $30.98 Million | +11.00% |
| 2022-12-31 | $27.91 Million | +33.35% |
| 2021-12-31 | $20.93 Million | -- |